BioMarin approval sets stage for revenue doubling, says William Blair

William Blair analyst Tim Lugo keeps an Outperform rating on BioMarin Pharmaceutical after the FDA approved the company’s Roctavian gene therapy for the treatment of severe hemophilia A in adult patients without a history of Factor VIII inhibitors and AAV5 antibodies. The approval represents a “transformational shift” for the severe hemophilia A community in the U.S. and paves the way for BioMarin to double its sales over the next three years, the analyst tells investors in a research note. The firm views BioMarin as a core holding.